US OptionsDetailed Quotes
EXAS250117C32500
- 37.90
- 0.000.00%
15min DelayClose Jan 3 16:00 ET
0.00High0.00Low
37.90Open37.90Pre Close0 Volume7 Open Interest32.50Strike Price0.00Turnover204.45%IV22.97%PremiumJan 17, 2025Expiry Date24.75Intrinsic Value100Multiplier11DDays to Expiry13.15Extrinsic Value100Contract SizeAmericanOptions Type0.9586Delta0.0042Gamma2.27Leverage Ratio-0.0805Theta0.0095Rho2.18Eff Leverage0.0091Vega
Exact Sciences Stock Discussion
Sign in to post a comment
Futures tied to the S&P 500 and the Dow soared to record highs on Wednesday as Republican Donald Trump won the 2024 U.S. presidential election, capping his return four years after he was voted out of the White House.
Market Snapshot
Dow E-minis were up 1,308 points, or 3.09%, S&P 500 E-minis were up 133.5 points, or 2.30% and Nasdaq 100 E-minis were up 374 points, or 1.84%.
Pre-M...
Market Snapshot
Dow E-minis were up 1,308 points, or 3.09%, S&P 500 E-minis were up 133.5 points, or 2.30% and Nasdaq 100 E-minis were up 374 points, or 1.84%.
Pre-M...
15
1
$Exact Sciences (EXAS.US)$ break 56.9 fly again
1
$Exact Sciences (EXAS.US)$ guys relax sooner or later this will grow just not so soon
1
1
$Exact Sciences (EXAS.US)$ whats happening? why it keeps dropping?
$Exact Sciences (EXAS.US)$ Good opportunity to buy after correction, "not today" I shall buy in next week once volatility minimized. Good AI stoks but you can see good return not before 2025. I am bullish on it and it will remain my best pick for next 3-5 years invetment tenure.
2
Exact Sciences' progress has failed to meet high market expectations, yet its consistent revenue growth suggests it may be worth further investigation. The company's performance has underperformed the broader market, which gained around 31%.
2
The company's strained balance sheet and lack of EBIT level profitability heighten risk. Its debt management and growth rate are key concerns, with faster growth expected from unprofitable firms.
Exact Sciences' low P/S ratio is due to its poor revenue outlook. Investors foresee limited growth, thus are only willing to pay less for the stock, making a strong share price rise unlikely.
No comment yet
Alen Kok : Oh